BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kjær MB, George J, Kazankov K, Grønbæk H. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Rev Gastroenterol Hepatol 2021;15:51-64. [PMID: 32878486 DOI: 10.1080/17474124.2020.1817740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wegrzyniak O, Rosestedt M, Eriksson O. Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:7348. [PMID: 34298967 DOI: 10.3390/ijms22147348] [Reference Citation Analysis]
2 Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Reference Citation Analysis]
3 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]